Monthly Dosing of Atacicept in IgAN
Trial details
- Registry ID
- NCT07020923
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as VT-001
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Monthly Dosing of Atacicept in IgANNCT07020923 | VERA | Phase 2 | Active not recruiting | 2026-09-22Actual |
| Atacicept in Multiple Glomerular DiseasesNCT06983028 | VERA | Phase 2 | Recruiting | 2027-11Estimated |
| Atacicept in Subjects With IgA NephropathyNCT04716231 | VERA | Phase 3 | Active not recruiting | 2025-05-15Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |